Maximising data capture in obesity trials
Global obesity trials are scaling fast with GLP‑1 therapies, making complete data capture essential to preserve scientific integrity and timelines. …
Global obesity trials are scaling fast with GLP‑1 therapies, making complete data capture essential to preserve scientific integrity and timelines. …
AstraZeneca’s investigational anti-fibril therapy, anselamimab, did not meet its primary endpoint in a Phase III trial in the overall light …
Dr Imogen Kretzschmar, consultant psychiatrist at Mamedica, examines medical cannabis's mental health benefits for patients under specialist supervision. Dr Imogen Kretzschmar, …
ConcertAI has announced enhancements to its CancerLinQ Suite, incorporating AI-driven trial matching and contextualised patient insights. These updates aim to support …
GSK and Ionis Pharmaceuticals’ genetic medicine, bepirovirsen, has demonstrated its functional curative potential in chronic hepatitis B (CHB) – a …
Kalohexis has dosed the first patients in its Phase I first-in-human clinical trial of 710GO, an oral dual melanocortin-3 receptor/melanocortin-4 …
Half of clinical trial experts asked in a recent survey cited trust and regulatory uncertainty as the major barriers to …
Hansa Biopharma’s Idefrix (imlifidase) has seen a 90% one-year survival from graft versus host disease (GvHD) in patients following a …
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has granted accelerated approval to its antiviral, Hepcludex …
The World Health Organization (WHO) published new data this month showing the impact of novel malaria vaccines in children. This …
Sobi has touted new efficacy results for Tryngolza (olezarsen) in severe hypertriglyceridemia, as the company and its commercial partner, Ionis …
Merck & Co (MSD) and Adcendo have entered a collaboration and supply agreement to evaluate ADCE-T02 with Keytruda (pembrolizumab) in …
Jade Biosciences has dosed the first participant in its Phase II JUNIPER clinical trial, evaluating JADE101 for immunoglobulin A nephropathy …
This is the first episode in our second season exploring the evolving landscape of real-world data and its role in …
Bial has completed the treatment in its Phase IIb ACTIVATE clinical trial evaluating BIA 28-6156 (pariceract) in Parkinson’s disease (PD) …